A Phase 1 interventional study of BMS-986365 and [14C] BMS-986365 in Healthy Volunteers, sponsored by Celgene. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-26.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to assess the pharmacokinetics (PK) and absolute bioavailability of BMS-986365 and to investigate the PK, metabolite profile, routes and extent of elimination, and mass balance of BMS-986365.
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
First submitted after Celgene became part of Bristol-Myers Squibb.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined Inclusion/Exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986365 · Drug: [14C] BMS-986365
Drug: [14C] BMS-986409 + BMS-986410
Drug: [14C] BMS-986410 + BMS-986409
Specified dose on specified days
Specified dose on specified days.
Specified dose on specified days
Specified dose on specified days
Maximum observed concentration (Cmax)
Part A and B
Time frame: Up to Day 60
Time of maximum observed concentration (Tmax)
Part A and B
Time frame: Up to Day 60
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Part A and B
Time frame: Up to Day 60
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC (INF))
Part A and B
Time frame: Up to Day 60
Apparent terminal plasma half-life (T-HALF)
Part A and B
Time frame: Up to Day 60
Total body clearance (CLT)
Part A
Time frame: Up to Day 15
Apparent total body clearance (CLT/F)
Part A and B
Time frame: Up to Day 60
Mean residence time (MRT)
Part A
Time frame: Up to Day 15
Apparent volume of distribution (Vz)
Part A
Time frame: Up to Day 15
Apparent volume of distribution (Vz/F)
Part A and B
Time frame: Up to Day 60
Absolute bioavailability (F)
Part A
Time frame: Up to Day 15
Number of participants with Adverse Events
Part A and B
Time frame: Up to Day 60
Number of participants with Serious Adverse Events
Part A and B
Time frame: Up to Day 60
Number of participants with AEs leading to discontinuation
Part A and B
Time frame: Up to Day 60
Number of participants with Vital sign abnormalities
Part A and B
Time frame: Up to Day 60
Number of participants with electrocardiogram (ECG) abnormalities
Part A and B
Time frame: Up to Day 60
Number of participants with physical examination abnormalities
Part A and B
Time frame: Up to Day 60
Number of participants with clinical laboratory abnormalities
Part A and B
Time frame: Up to Day 60
Ran from May 2024 to primary completion in Feb 2025, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dezandrodeg